Impact - The Jimmy Fund

Impact
SPRING 2010
dana-farber.org and jimmyfund.org
THANKING THOSE WHO MAKE A DIFFERENCE.
Volume 13 • Issue 1
Dana-Farber Marathon Challenge runners
stay on course to conquer cancer
3
PMC
Powers Ahead
After many dedicated months of training runs, nursing
injuries, and plenty of fundraising, more than
550 members of the 2010 Dana-Farber Marathon
Challenge (DFMC) team excitedly lined up at the start of the
114th Boston Marathon® April 19 to race 26.2 miles in support
of the Claudia Adams Barr Program in Innovative Basic
Cancer Research.
The Barr Program was founded in 1987 by Institute
Trustees J. Wayne and Delores Barr Weaver in memory
of Delores’ mother to fund groundbreaking basic research
into the molecular genetics, biology, biochemistry, and
epidemiology of cancer at DFCI. Since its inception, the
DFMC team has collectively raised more than $43 million
toward these initiatives.
“It is truly wonderful that the DFMC team is entering its
third decade of racing and fundraising,” said Delores Barr
continued on page 14
7
Senator
Supports DFCI
8
Running
on Plenty
13
Foundation
Fuels Hope
The 21st annual Dana-Farber Marathon Challenge team gathers in Hopkinton, Mass., before the start of the 114th Boston Marathon ® .
15
A Friend
Remembered
Young scientists get ‘a leg up’ from Stand Up To Cancer grants
Stand Up To Cancer (SU2C) is a galvanizing fundraising initiative to
accelerate groundbreaking translational cancer research that will rapidly lead
to new treatments. A program of the Entertainment Industry Foundation
(EIF), SU2C recently awarded $9.68 million in Innovative Research Grants to
support 13 young scientists across the U.S., with Dana-Farber earning the highest
number of grants.
Four DFCI investigators—Loren Walensky, MD, PhD, medical director of
Cancer Chemical Biology; Charles Roberts, MD, PhD, and Kim Stegmaier, MD,
of Pediatric Oncology; and David Weinstock, MD, of Hematologic Oncology—
will each receive $750,000 over a three-year period, totaling $3 million in support.
“To have four grant recipients is a great honor for Dana-Farber,” said Institute
President and CEO Edward J. Benz Jr., MD. “This success speaks to the quality of
our young investigators, the promise of their research and vision, and the investments
we have made in turning scientific discoveries into new therapies for patients.”
High-risk, high-reward projects
The innovative studies funded by the SU2C grants are characterized as “high
risk” because they challenge existing paradigms and typically do not have enough
preliminary data to successfully compete for government grants. The projects have
enormous potential for a great payoff in terms of therapeutic strategies that will
help patients live longer, healthier lives.
“We are at a very important juncture in cancer research. New technologies
have increased the speed of progress, and we now have the ability to move new
discoveries out of the lab and into the clinic,” said Margaret Foti, PhD, MD (hc),
chief executive officer of the American Association for Cancer Research
(AACR), the sole scientific partner to SU2C. “Support for talented young
“Support for talented young scientists is critical to
ensuring that we continue the fight against cancer.”
— Margaret Foti, Phd, MD (hc)
scientists is critical to ensuring that we continue the fight against cancer.”
As a collaborator, the AACR conducts expert peer review and oversees grants
administration for SU2C in a rigorous and transparent manner.
The SU2C grant will fuel Walensky’s research to identify, characterize, and
target a broad spectrum of cancer-causing protein interactions. Uncovering the
specific sites of interaction, which Walensky refers to as “molecular handshakes,”
continued on page 13

Build the future in the new Yawkey Center for Cancer Care at dana-farber.org/yccc.
Dear Friends,
In this time of astonishing scientific discovery, a
revolution in cancer care is occurring as Dana-
Farber works to accelerate the development of
drugs that are tailor-made to counteract the
distinct genetic errors that have caused tumors
to occur. This approach, known as personalized
medicine, determines treatment decisions based on a patient’s genetic profile
and works by giving the right drug, to the right patient, at the right time.
In this issue of Impact, we are thrilled to recognize those donors who
have joined together to bring us ever closer to the delivery of this new
standard of individualized cancer care.
We are thrilled to thank the Palm Beach, Fla., community for the $1.3
million they raised to support cancer research and patient care through their
annual season of fundraising, including the 19th annual Discovery Ball
held Feb. 20 at The Breakers Hotel. We thank Co-chairs Sheila Palandjian,
Institute Trustee Peter Palandjian, Leon Palandjian, and Vice Chair
Patrick Park, along with the many committee members and attendees, for
producing a truly successful event.
We are also delighted to thank the 559 runners who braved a grueling
26.2 miles April 19 as part of the Dana-Farber Marathon Challenge team.
The anticipated $4.4 million fundraising total is set to benefit the Claudia
Adams Barr Program in Innovative Basic Cancer Research, which funds
critical studies in basic cancer biology.
Meanwhile, the grassroots strength of the Stand Up To Cancer program
has resulted in $3 million in grants to fund the work of several of Dana-
Farber’s most promising researchers. This support will accelerate the speed
at which lab discoveries are transformed into effective new treatments for
all forms of cancer.
Dana-Farber continues to translate this fundraising success into tangible
progress in cancer care, cutting-edge research, and community outreach.
Thank you all for your continued dedication to our lifesaving mission, which
is helping us usher in a new and exciting era of cancer research and care.
In closing, I am happy to welcome Boston Red Sox pitchers Clay
Buchholz and Tim Wakefield as Co-captains of the Jimmy Fund. We
are honored to have them on our team as ambassadors, helping to drive
support for cancer research and care.
Sincerely,
As Dana-Farber continues to raise funds through the close of the Mission
Possible Campaign and beyond, one of the areas on which we will
continue to focus our fundraising efforts is the Yawkey Center for Cancer
Care, which represents the future of cancer care for our patients.
The Yawkey Center has been designed to complement Dana-Farber’s
50-50 balance between research and care, so that patients continue to
receive the most optimal care to combat their cancer. The Institute’s
commitment to this is unique among cancer centers and results in
an extraordinary level of collaboration and partnership among our
laboratory scientists, clinicians, and patients. It is at this interface that
translational research occurs, fostering the rapid translation of scientific
discoveries into lifesaving treatments for patients.
Hundreds of donors have seen the promise of this new facility and have
made generous gifts during the Campaign to support the Yawkey Center.
As of April 30, we have raised $136 million toward our $150 million
Campaign goal for this new building.
One area of the Yawkey Center that demonstrates just how unique this
building will be is the Early Drug Development Center (EDDC). Housed
on the sixth floor, the EDDC will focus on conducting phase I clinical
trials: small, carefully designed safety studies of experimental drugs that
are being given to patients for the first time. These efforts will bring us
steps closer to developing “smart” clinical trials based on the genetics of
a patient’s tumor.
“The Yawkey Center will be critical to our efforts as we usher in a new era
of personalized medicine,” said DFCI President and CEO Edward J. Benz
Jr., MD. “And it will foster the strong spirit of teamwork that sets Dana-
Farber apart from other cancer institutions.”
Making the vision for this building a reality requires a tremendous
amount of support. Continued generosity from our loyal community of
donors for the Yawkey Center and Mission Possible Campaign will provide
important momentum toward our ultimate goal of conquering cancer.
Susan S. Paresky
Senior Vice President for Development
To support the Yawkey Center for Cancer Care and help make our
mission possible, please contact Patty Brent, director of Individual
Giving, at 617-632-2443 or patricia_brent@dfci.harvard.edu.
*Message and data rates apply.Ten dollars billed to your cell phone. Terms: hmgf.org/t
Impact Spring 2010
Volume 13 • Issue 1
This issue covers gifts received and finalized through
the Spring of 2010.
President, Dana-Farber Cancer Institute Edward J. Benz Jr., MD
Chief Clinical Research Officer Philip W. Kantoff, MD
Chief Medical Officer Lawrence Shulman, MD
Chief Scientific Officer Barrett J. Rollins, MD, PhD
Chief of Staff Stephen E. Sallan, MD
Chair of Executive Committee for Research David M. Livingston, MD
Chair of Medical Oncology James Griffin, MD
Chair of Pediatric Oncology Stuart H. Orkin, MD
Chair of Psychosocial Oncology and Palliative Care Susan Block, MD
Chair of Radiation Oncology Jay R. Harris, MD
Chief of Radiology Annick D. Van den Abbeele, MD
Senior Vice President for Experimental Medicine Lee M. Nadler, MD
Senior Vice President for Patient Care Services, Chief Nurse
Patricia Reid Ponte, RN, DNSc, FAAN
Senior Vice President for Research Beverly R. Ginsburg-Cooper, MBA
Senior Vice President for Development Susan S. Paresky
Senior Vice President for Communications Steven R. Singer
Assistant Vice President, Development Marketing and Donor Relations
Jan Lawlor
Impact Editor Brian Geer
Assistant Editor Lauren Carr
Contributors Amy Barberie, Jared Berezin, Courtney Blenheim,
Alan Caplan, Brenda Chroniak, Kevin Collins, David Ferreira,
Georgina Morales Hampe, Daniel Morris, Liz Nelson, Robin
Orwant, Beth Rossi, Diane Schmidt, Coral Vogel, Lindsay Wilber
Art Director Alan Caplan
Designer Sharon Veino
Production Coordinators Maria Cipicchio, Georgina Morales Hampe
Photographers Lucien Capehart Photography, John Deputy, Steve
Gilbert, Channing Johnson, Justin Knight, Susan Korsmeyer, Kelly
Lorenz, Steve McLaughlin, Sam Ogden, Aaron Washington
Impact is a quarterly newsletter of Dana-Farber Cancer Institute
published by the Division of Development and the Jimmy Fund.
To be removed from our mailing list, please contact:
DFCI Development Office
10 Brookline Place West, 6th Floor
Brookline, MA 02445-7226
617-632-3019 or 800-52-JIMMY
or visit jimmyfund.org/opt-out
Dana-Farber Cancer Institute provides expert, compassionate care
to children and adults and is home to groundbreaking cancer
discoveries. Since its founding in 1948, the Jimmy Fund has raised
millions of dollars through thousands of community efforts to
advance Dana-Farber’s lifesaving mission.
2
Impact SPRING 2010

Komen grant promotes
studies into chemotherapy
resistance
Even as she struggled with her own failing health, Susan G. Komen inspired
those around her—including her sister, Nancy Brinker—with her compassion
for others and her commitment to making a difference. Nancy promised
“Suzy” she would do everything in her power to end breast cancer forever.
This promise evolved into Susan G. Komen for the Cure, a foundation dedicated
to the sisters’ joint mission to empower
and improve the lives of all
women with this disease.
Now, continuing its longstanding
partnership with Dana-Farber, Susan
G. Komen for the Cure has awarded
a grant of $600,000 to the team of
Andrea Richardson, MD, PhD, and
Zhigang Wang, PhD, in DFCI’s
Women’s Cancers Program.
“We have every confidence that these outstanding investigators have the
potential to make great inroads and bring us closer to effective treatments and,
one day, a cure,” said Elizabeth Thompson, Komen’s vice president of Health
Science.
Richardson and Wang recently discovered a genetic alteration in breast cancers
that appears to contribute to chemotherapy resistance. Extra copies of this gene
create high levels of a particular protein, which may well prevent chemotherapy
from reaching the cell nucleus and destroying the malignant tumors. As a result,
this raises the risk of the cancer metastasizing. With their grant, Richardson and
Wang will investigate how this happens, whether the protein can be used as a
biomarker to predict a patient’s response to chemotherapy, and whether it can be
shut down by a new targeted therapy.
“We have every confidence that these outstanding
investigators have the potential to make great
inroads and bring us closer to effective treatments
and, one day, a cure.”
— Elizabeth Thompson
“We are tremendously grateful to Susan G. Komen for the Cure for its
support of these investigations,” said Richardson. “One immediate benefit of
our research is that if we know a patient’s breast cancer is unlikely to respond
to standard chemotherapy because it has excessive quantities of this protein, we
can choose alternative treatment at the outset and help prevent the disease from
spreading.” Richardson hopes that this protein could also provide an important
new target for therapy and a key to selecting the most effective treatment
for patients. n
Create a personalized web page to honor
a loved one, mark a special occasion or life
event, and raise funds for Dana-Farber and
the Jimmy Fund. Make the fight against
cancer even more personal.
GET CONNECTED TODAY AT together4cures.org
Pan-Massachusetts Challenge:
A history of success
Last summer, 4,937 riders and a record-breaking 3,000 volunteers gathered across
the Commonwealth to take part in the 30th Pan-Massachusetts Challenge (PMC)
bike-a-thon. Held in August, the PMC featured two days of riding on routes ranging
from 47 – 190 miles. Dedicated cyclists, virtual fundraisers, and volunteers, along
with the support of the event’s sponsors—the Red Sox Foundation, Overstock.com,
New Balance, Stop & Shop, MFS Investment Management, and New England Cable
News—all contributed in a large way, raising $30.38 million for Dana-Farber’s fight
against cancer.
Above: On Dec. 5 at the House of Blues in Boston, PMC Founder and Executive Director
Billy Starr (left), who is also an Institute trustee, and PMC Board of Directors Chairman
Gordon Prichett (right) presented a check to DFCI President and CEO Edward J. Benz Jr.,
MD, representing the PMC’s 30-year fundraising total of $270 million. The annual bikea-thon
has grown considerably since its inception in 1980, when 36 riders recruited by
Starr covered 220 miles and raised more than $10,000. With its success in 2009, the PMC
cemented its status as the nation’s largest and most successful athletic fundraiser and the
Jimmy Fund’s single largest contributor.
National Brain Tumor Society
gift establishes international
pediatric tissue bank at DFCI
In its ongoing commitment to fund groundbreaking research, the National
Brain Tumor Society, in collaboration with the Pediatric Low Grade
Astrocytoma Foundation, has awarded Charles Stiles, PhD, co-chair of Cancer
Biology and co-director of the
Pediatric Low-Grade Astrocytoma
(LGA) program at Dana-Farber,
$180,000 to coordinate and
oversee the creation of the first
international pediatric low-grade astrocytoma tissue bank at Dana-Farber.
LGAs are solid tumors found in the brain and spinal cord that require
physically challenging chemotherapy and radiation treatments, and have
surpassed leukemia as the leading cause of pediatric cancer deaths.
“Establishing this tissue bank is a major step in advancing much needed
pediatric LGA research,” said the National Brain Tumor Society’s Chief Scientific
Officer David R. Hurwitz, PhD. “Dr. Stiles, his colleagues, and their teams have
the highest level of expertise and the ability to develop and maintain this vital
tissue bank.”
This award is especially significant in that it will help acquire diverse samples
of pediatric LGA tumor tissues that have previously been difficult to find for
research purposes. The samples will be obtained from several institutions,
including Children’s Memorial Medical Center in Chicago, Ill., Johns Hopkins
University School of Medicine in Baltimore, Md., Washington University School
of Medicine in St. Louis, Mo., and hospitals in Cairo, New Delhi, and Istanbul.
The gift will also allow Yongji Tian, MD, from Beijing’s Tiantan Hospital, to
come to Boston for one year to assist in the banking of the samples. Once banked,
the samples will be analyzed by Levi Garraway, MD, PhD, of DFCI’s Center for
Cancer Genome Discovery and the Broad Institute of Harvard and MIT.
“It is extremely beneficial having several institutions involved in these
studies,” said Stiles. “This tissue bank allows for genetic analysis and profiling
of the tumor samples that will help in better understanding the disease and,
ultimately, finding targeted therapies.” n
Impact SPRING 2010 3

A community unites:
Palm Beach raises
$1.3 million for DFCI
Once again, Dana-Farber’s numerous friends and supporters in Palm
Beach, Fla., joined together to show their enduring commitment to
conquering cancer through a series of benefit events last winter. This
2010 fundraising season was highlighted by the 19th annual Discovery Ball,
where it was announced that $1.3 million had been raised toward the Institute’s
cancer care and research initiatives.
“For 19 years, the Palm Beach community has exhibited a passionate connection
to Dana-Farber’s lifesaving mission,” said Institute President and CEO Edward J.
Benz Jr., MD. “On behalf of everyone at DFCI—most especially our patients and
their families—I extend my heartfelt gratitude for their lasting generosity.”
The season commenced Jan. 13 at a Kick-off Party held at the Mar-a-Lago
Club, hosted and underwritten by Discovery Ball Vice Chair Patrick Park. The
evening featured delicious cocktails and hors d’oeuvres, as well as an informal
fashion presentation of Naeem Khan’s Spring 2010 collection, presented by
Neiman Marcus.
The ball celebrations got underway Feb. 18 as bronze-level donors gathered at
the homes of hosts Phyllis and Paul Fireman, Kate Ford and Frank Chopin, Sydell
Miller and Phil Zieky, and Tom Quick for a series of intimate Pre-Ball dinners.
On Feb. 19, the ninth annual Breakfast with the Doctors event, hosted and
underwritten by Institute Trustee Judie Schlager, her husband, Larry, and Vicki
and Arthur Loring, was held at the Palm Beach Country Club. A panel comprised
of top Dana-Farber physician-scientists provided recent updates on significant
research breakthroughs and answered questions posed by the attendees.
The next night, Co-chairs Sheila Palandjian, Institute Trustee Peter Palandjian,
and Leon Palandjian welcomed 350 guests to the elegant Discovery Ball in the
Venetian Ballroom at The Breakers. Attendees gathered to dine, dance, and
celebrate their fundraising success amidst a gorgeous décor of elegant white
flowers and lively music played by the Greg Denard Orchestra. Beautiful crystal
water pitchers, compliments of Tiffany & Co., provided attendees with a special
remembrance of the evening.
The season culminated March 16 with the Major Donor Dinner, hosted by
former Trustee James W. Harpel, where event chairs, sponsors, and major silverlevel
donors toasted the end of another very successful season. n
Left to right: Chairs of the Discovery Ball and Grand Patrons, the Palandjian family—Minou, Institute
Trustee Peter, Sheila, Leon, and Tracy—celebrate a successful fundraising season.
Discovery Ball Dinner Chair Bonnie Dwares
and her husband, Donald, an Institute trustee,
are perennial Palm Beach supporters.
Silver Donor Tom Quick hosted a Pre-Ball Dinner.
Major Donor Dinner Chair James W. Harpel
served as Grand Patron of the Discovery Ball.
Gold Donors Frank Chopin and Kate Ford
opened up their home for a Pre-Ball Dinner.
Grand Patrons Howard Kessler and his wife,
Michele, an Institute trustee, served as Honorary
Chairs of the Discovery Ball.
Grand Benefactors and Pre-Ball Dinner Hosts
Phyllis and Paul Fireman will co-chair the 2011
Discovery Ball.
Gold Donors Judie Schlager (second from left), an Institute trustee, her husband, Larry (left), and Vicki and
Arthur Loring hosted the annual Breakfast with the Doctors event.
Corporate Platinum Donor Tiffany & Co.’s
Rebecca Brewer (left) and Gina and Jeff Sabean
celebrate the Discovery Ball’s success.
Silver Donors and Pre-Ball Dinner Hosts
Sydell Miller and Phil Zieky enjoy the
evening’s festivities.
Patrick Park (pictured with Nathalie Fernandez) held two titles: Discovery Ball Vice Chair
and Kick-off Party Chair.
4
Impact SPRING 2010

Follow the Jimmy Fund on Twitter and Facebook.
Foundation augments pediatric brain tumor
program with new support
In 2007, the founding families of the Pediatric Low Grade Astrocytoma (PLGA)
Foundation supported the creation of a program at DFCI for what is believed
to be the first coordinated effort focusing on PLGAs, with a five-year objective
of identifying molecular targets that can be treated with targeted therapies. Today,
the PLGA Foundation is renewing that commitment with two additional grants
totaling $501,529 in support of Mark Kieran, MD, PhD, director of Pediatric
Medical Neuro-Oncology, and to fund a pathology research scientist post,
currently held by Benjamin Rich, MD, under the direction of Charles Stiles, PhD,
co-chair of the Department of Cancer Biology.
“PLGAs are the most common brain tumor in
children, but there has not been a change in
frontline treatment for more than 25 years.”
— Andrew Janower
Left to right: The PLGA Foundation’s John Ragnoni, DFCI’s Mark Kieran, MD, PhD, and Charles Stiles, PhD,
Ken Gainey and Andrew Janower of the PLGA Foundation, and DFCI’s Deborah Goff, PhD, discuss the
future of PLGA research at Dana-Farber.
PLGAs are slow-growing brain tumors, from which more than 70 percent of
patients survive. However, recurrence is common, and repeated cycles of treatment
have a high likelihood of causing growth and cognitive abnormalities. Rich will
work alongside DFCI’s Keith Ligon, MD, PhD, director of the Dana-Farber/
Brigham and Women’s Neuro-Oncology Living Tissue Bank, to map genomic
characterizations of tumor samples acquired through the PLGA program’s national
and international partnerships.
These partnerships will prove vital in helping to gather thousands of new tissue
samples and lead to future recruitment of patients into clinical trials to test new
targeted therapeutics.
“PLGAs are the most common brain tumor in children, but there has not been
a change in frontline treatment for more than 25 years,” said Foundation President
Andrew Janower. “By genotyping these tumor samples, we can find the genetic
mutations that drive this cancer, providing researchers and clinicians with the
information needed to develop more effective and less toxic targeted therapies.”
Concurrently, Kieran is directing a multi-institutional clinical trial for children
with recurrent or progressive PLGAs. The latest additional support from the
PLGA Foundation will allow Kieran to focus on overcoming regulatory hurdles for
current and pending clinical trials, as well as continuing to acquire tissue samples
with the goal of creating a comprehensive LGA tissue registry.
“For the first time, we are developing treatments that target some known
mutations that spur certain PLGA tumors,” said Kieran. “Instead of treating young
children with toxic radiation and chemotherapy, we will be able to use these targeted
drugs to stop just the mutated proteins, while leaving all the healthy cells alone.” n
On the agenda:
A new model of cancer research
The Dana-Farber Visiting Committees, consisting of Institute trustees and business and
community leaders who share a passionate dedication to the Institute, gathered for their
sixth annual meeting Nov. 19 to reflect on DFCI’s “New Model of Cancer Research—5
Years On.” The Visiting Committee for the Women’s Cancers Program met separately
Oct. 21.
To kick off the symposium, a dinner was held at The Colonnade Hotel in Boston,
featuring keynote speaker Julio Frenk, MD, MPH, PhD, dean of the Faculty, Harvard
School of Public Health (left, with his wife, Felicia Marie Knaul, PhD, and Institute
President and CEO Edward J. Benz Jr., MD). Frenk, the T and G Angelopoulos Professor
of Public Health and International Development at HSPH, is also the former Minister
of Health of Mexico.
The next day, Visiting Committees for the Gastrointestinal Cancer Center, Hematologic
Oncology, Jimmy Fund, Lank Center for Genitourinary Oncology, and Lowe Center
for Thoracic Oncology convened in a Joint Plenary Session. The group discussed
Dana-Farber’s accomplishments and next steps in its war on cancer through an
open dialogue, moderated by Institute Trustee Alan Hirschfield, with Benz and Chief
Scientific Officer Barrett Rollins, MD, PhD. The committees then met to hear about
updates, discoveries, and challenges in their respective disease and program areas.
The Greenwall Foundation
supports study into ethics
and clinical trials
Dana-Farber’s ultimate mission is to conquer cancer, AIDS, and related
diseases, as well as the fears that they engender. Clinical research is
integral to achieving this vision, and Institute leaders have long stipulated
that this research be done in the most
ethical way possible.
To further support important
clinical research, the Greenwall
Foundation recently named Dana-
Farber’s Steven Joffe, MD, MPH,
as a Greenwall Faculty Scholar. This
$350,000 award will fund his research
analyzing the ethical challenges that
arise in conducting clinical trials.
“The Greenwall Faculty Scholars
Board is pleased that Steven Joffe has
been selected,” said Bernard Lo, MD,
director of the Greenwall Faculty
Scholars Program. “He has already
carried out a distinguished scholarship
regarding research ethics, and we are
confident that this award will allow
him to develop new lines of research
in bioethics.”
Joffe aims to systematically analyze
the ways in which individuals and
Steven Joffe, MD, MPH, studies the ethical
challenges that arise in conducting clinical
investigations.
organizations are held responsible
for their actions and decisions in
clinical studies, focusing on two
important players in clinical trials:
principal investigators and institutional review boards.
“This grant allows me to explore an overarching theme in my work:
accountability,” said Joffe. “It is an important opportunity to tie together all
of my research from the past 10 years, while also shaping the direction of my
research for the next 10.” n
Impact SPRING 2010 5

American Cancer Society grants propel cutting-edge research
The relationship between the American Cancer Society (ACS) and Dana-
Farber spans more than 60 years, beginning with the society’s support for
Institute Founder Sidney Farber, MD, and his innovative research into
childhood leukemia. As the nation’s largest
nonprofit source of funding for scientists
researching cancer in the U.S., the ACS has
granted $3.4 billion since 1946. Dana-Farber
has been the recipient of nearly $40 million
of that funding over the years.
Most recently, the Institute’s researchers
were awarded more than $1.38 million
to further their studies. The recipients of these grants—Adam Boutin, PhD;
Lawrence Kwong, PhD; Jennifer Perry, PhD; and Kimberly Stegmaier, MD—are
all working to keep the DFCI/ACS partnership thriving.
“We take a great deal of pride in having awarded funding to some of the most
talented investigators in the nation at Dana-Farber,” said Donald J. Gudaitis, CEO
of the American Cancer Society, New England Division. “We have seen impressive
results from these scientists in high-impact areas, ranging from chemotherapy and
chromosome composition biology to the effect of acupuncture on the quality of
life for patients with late-stage cancers.”
Moving novel research forward
The grant for Stegmaier’s research will further her investigation into novel
treatments for acute myeloid leukemia (AML) through a series of preclinical
studies aiming to validate a new protein target for therapy.
“We take a great deal of pride in having awarded
funding to some of the most talented investigators
in the nation at Dana-Farber.”
— Donald J. Gudaitis
“Grants such as the ACS award are essential for the success of my research
program because of the strong emphasis on translation,” explained Stegmaier.
“Historically, it has been quite difficult to secure funding, such as government-based
grants, for translational research, and the ACS funding will support the necessary
preclinical studies.”
The other DFCI physician-scientists honored by the society are also engaged
in work that will get a needed boost. Boutin’s grant will back his investigations
into the genetics of colon cancer metastasis, which he hopes will lead to a better
understanding of the disease.
Kwong’s funding will further his research into a specific gene found in
melanoma tumors and its relationship to suppression of this type of skin cancer.
In addition, ACS’ support will help Perry study the effects of a particular group
of proteins called polycomb proteins and their effect on tumor formation.
“Ultimately, the American Cancer Society’s efforts to fund the most innovative
and significant research possible will help us continue our fight to reduce the burden
of cancer and create a world with more birthdays,” explained Gudaitis. “We are
proud to partner with Dana-Farber in making an investment in that future.” n
Trust family displays
faith in DFCI’s kidney
cancer research
Dena and Martin Trust’s belief that Dana-Farber can conquer cancer has led
the couple to support the Institute for nearly two decades. Most recently,
they reaffirmed this commitment with a $250,000 gift to create the
Trust Family Research Fund for Kidney Cancer at Dana-Farber. Managed under
the direction of Toni Choueiri, MD, this gift also provides support for Mission
Possible: The Dana-Farber Campaign to Conquer Cancer.
Despite recent breakthroughs, kidney cancer research is an area that has
struggled for funding from
traditional sources. Thus,
philanthropic support is critical to
driving these investigations forward.
“The Trusts’ gift is essential to
expanding Dana-Farber’s clinical
research platform in kidney cancer,”
said Choueiri. “It has given us the
resources necessary to execute a great
deal of new and exciting projects.”
The ultimate goal of Choueiri’s
clinical research is to understand
better the genetic mutations that
give rise to the disease and target
them with novel therapeutics.
The Trusts’ gift will enhance the
specimen repository at Dana-
Farber, thereby providing more
adequate tissue samples for
researchers to analyze. In addition,
their gift has helped to recruit Fabio
Schutz, MD, a research associate
focused specifically on conducting
this research.
“With the leadership of Drs.
Choueiri and Schutz, it is clear to
us that the projects are in extremely
capable hands,” said Martin Trust.
“We are pleased to give to Dana-
Farber because we know that these
Dena and Martin Trust’s support is playing a pivotal
role in advancing Dana-Farber’s kidney cancer
research initiatives.
funds will be used to produce
significant results.” n
We know the answer
to conquering cancer
is Dana-Farber.
With support,
The Jones Family
ACTUAL GENE IS 4” X 4”
Name a gene.
Make your mark on cancer.
Be part of the cancer revolution. Name a gene at Dana-Farber.
This visual and dynamic display represents the real genetic
information that leads us to lifesaving cancer treatments.
Show your support by naming a 4-inch-square gene with a
personal message in honor of a family member, friend, or caregiver.
For more information, contact:
Zach Dubin
617.582.8830
gene_display@dfci.harvard.edu
NameAGene.org
6
Impact SPRING 2010

Get Jimmy Fund event coupons, updates, and wallpapers at jimmyfund.org/mobile.
Nuclea Biotechnologies
promotes development
of diagnostic tools
Nuclea Biotechnologies, LLC, and Dana-Farber’s Center for Molecular
Oncologic Pathology (CMOP) Director Massimo Loda, MD, share
a common vision for the future of cancer care. In their ideal world,
pathologists analyzing biopsied
tumors would have the ability
to immediately diagnose cancers
on a genetic and molecular
level, giving doctors the
information they need to get
the right drugs into the right
patients as quickly as possible.
To help realize this dream,
Nuclea recently gave Dana-
Farber $470,000 to fund
ongoing research in Loda’s
laboratory and further the
Patrick Muraca (fourth from left), president and CEO of
Nuclea Biotechnologies, LLC, and his staff are proud to
support the development of new cancer diagnostic tools
at Dana-Farber.
CMOP’s mission.
“Nuclea is proud to support
Dr. Loda’s work into the
detection of cancer-promoting
genes and molecules in tumor
tissue samples,” said Patrick Muraca, president and CEO of the biotechnology
services company. “Our hope is that, one day, these efforts will transform the
standard of care for all cancer patients.”
The gift, the latest of several made by Nuclea to Dana-Farber over the years,
will help cover Loda’s operational, administrative, and research costs. A significant
portion of the funds will fuel a number of exciting new research projects aimed at
revolutionizing the way human cancers are diagnosed.
“This gift gives us the flexibility to try innovative experiments that most
traditional funding organizations won’t touch,” said Loda. “Aid like this is
critical because it helps us make those initial discoveries that will garner
broader support later on.” n
QVC ® and FFANY mark 16
years in their fashionable
fight against breast cancer
QVC®, Inc., and the Fashion Footwear Association of New York (FFANY)
put their best feet forward Oct. 13 at the 16th annual QVC presents
“FFANY Shoes on Sale” event, raising more than $2.5 million for breast
Left to right: FFANY Chairman Larry Tarica; Fashion Footwear Charitable Foundation Chairman Joseph
C. Moore; DFCI’s Breast Oncology Center Director Eric Winer, MD; DFCI’s Program for Young Women
with Breast Cancer Director Ann Partridge, MD, MPH; and QVC, Inc., President and CEO Mike George
celebrate the 16th annual QVC Presents “FFANY Shoes on Sale ® ” event.
cancer research and education. During the annual fundraiser, which was held in
New York City and broadcast live over the QVC network, more than 100,000
pairs of designer and brand-name shoes were offered at half the manufacturers’
suggested retail prices. Proceeds benefited eight premier breast cancer programs
nationwide, including that within the Women’s Cancers Program at Dana-Farber.
Attendees joined celebrity spokesperson Jessica Simpson at the Frederick P.
Rose Hall, home of Jazz at Lincoln Center, for live music, cocktails, and
hors d’oeuvres, while shopping in the venue’s expanded designer shoe salon.
With more than 1 million pairs of shoes sold since the event’s inception in
1993, QVC presents “FFANY Shoes on Sale” 2009 is expected to bring the
cumulative total raised for breast cancer to nearly $32.5 million, with the Women’s
Cancers Program at DFCI receiving more than $3 million over the years.
“For 16 years, QVC and FFANY have played a vital role in advancing
critical breast cancer research and education,” said Eric Winer, MD, director
of the Breast Oncology Center at Dana-Farber. “Their dedication provides the
momentum we need to change the way we understand and treat breast cancer,
ultimately offering hope to patients everywhere.” n
A friend remembered
Bridget Slotemaker, 35, was a devoted wife and mother of two whose life was tragically
cut short after a brief but brave battle against cancer. Nearly two years after Slotemaker’s
passing in August 2008, her friends and family came together to celebrate
her memory with the second annual An Evening for Bridget, held Feb. 6 at the Boston
Harbor Hotel at Rowes Wharf. Nearly 300 guests turned out for an event that included
cocktails, dancing, silent and live auctions, and an array of guest speakers, including
WCVB-TV Channel 5 reporters Kelley Tuthill (left) and Gail Huff, and Huff’s husband, U.S.
Senator (R-MA) Scott Brown (right).
The generosity of attendees and sponsors helped the evening raise more than $100,000
for Dana-Farber and its mission to conquer breast cancer—a feat that Slotemaker’s
loved ones know would have made her very happy.
REGISTER TODAY at JimmyFundWalk.org
$5 off registration with promo code: IMPACT
SUNDAY, SEPTEMBER 12
CONQUER CANCER
Impact SPRING 2010 7

The race to conquer cancer:
Dana-Farber runners
reach new milestone
On a crisp and sunny October morning, a field of more than 5,000 worldclass
athletes and running enthusiasts raced 13.1 miles along Boston’s
famed Emerald Necklace park system during the 2009 B.A.A. Half
Marathon®, presented by Dana-Farber Cancer Institute and the Jimmy Fund. Of
those participants, 471 race entrants laced up their running shoes as part of the
official Dana-Farber team, sprinting to an all-time high fundraising total of more
than $437,700—contributing to the more than $2 million raised through this event
over the last seven years.
“The B.A.A. is proud of its more than 20-year partnership with Dana-Farber and
the Jimmy Fund to conquer cancer,” said Guy L. Morse III, executive director of
the Boston Athletic Association. “The battle against cancer is a marathon in its own
right, and we congratulate Dana-Farber as it moves closer to the finish line.”
Members of the official Dana-Farber team in the B.A.A. Half Marathon prepare to take on the
13.1-mile course.
The ninth annual B.A.A. Half Marathon celebrated its largest field of entrants,
official starters, and finishers in its history, selling out entries within 26 hours. This
year’s Dana-Farber team included runners from 21 states, as well as Mexico City
and Rio de Janeiro. Holding the finish line tape for the race’s men’s champion was
DFCI patient partner Jaden Cabrera, 6, of Peabody, Mass., who was diagnosed in
2007 with Burkitt’s lymphoma. The team hero was Drew Pelletrino, 8, of Beverly,
Mass., a DFCI patient partner diagnosed with lymphoma in 2005, who motivated
the runners to go the extra mile in their training and fundraising efforts.
“Drew and Jaden are endlessly inspiring individuals and living proof that the
funds raised for the Jimmy Fund are making a significant difference in cancer care
and research,” said Jimmy Fund Director Suzanne Fountain. n
Four-time melanoma
survivor provides support for
Dana-Farber researcher
When Emily “Luli”
MacNaught first met
Dana-Farber’s F. Stephen
Hodi, MD, she knew she had found
an important ally in her battle against
melanoma. Intrigued by Hodi’s investigations
on this relatively rare form
of skin cancer, she and her husband
later established the Malcolm and
Emily MacNaught Fund for Melanoma
Research to fuel the physicianscientist’s
work.
Recently, the couple reaffirmed
their commitment to this mission
by contributing another $100,000
to their fund. The gift also supports
Mission Possible: The Dana-Farber
Campaign to Conquer Cancer.
“My wife is one of the lucky
ones, but not everyone is so lucky,”
Luli and Malcolm MacNaught are helping Dana-
Farber’s F. Stephen Hodi, MD, study
the molecular effects of a potential new therapy
in melanoma patients.
said Malcolm MacNaught, reflecting on the recent loss of a close friend to
melanoma. “These studies are too important to be held up by a lack of funds.”
The MacNaughts were inspired to expand their support when Hodi, now
director of the Melanoma Center at Dana-Farber/Brigham and Women’s Cancer
Center, told them about a new type of drug called a CDK inhibitor, which he
plans to test as a potential therapy in melanoma patients. The gift will allow
Hodi to monitor patient reactions to the drug on a molecular level, gathering
information that will be critical to understanding how and why specific patients
do or do not respond to this treatment.
“If we want to learn which drugs work best for which patients, we have to
do these types of studies,” said Hodi. “Unfortunately, it’s sometimes hard to get
government funding for them, which is why private philanthropic support from
people like the MacNaughts is so essential.” n
Fashion-forward fundraising success
The 11th annual Saks Fifth Avenue “Key To The Cure” shopping event was held
Oct. 15 – 18 to benefit the all-volunteer Friends of Dana-Farber Cancer Institute. The
four-day event began in style with “Catwalk for the Cause” and a morning of fashion,
fine food, and shopping with members of the Friends, their guests, and event sponsors
modeling the hottest trends of the season. Saks pledged 2 percent of all sales during
the weekend to help fight women’s cancers, raising more than $50,000 for the Gillette
Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer Center.
Above: Following opening remarks from event Co-chair Dana Gerson Unger, Friends
board member Kristienne Rassiger showed off fall fashions during “Catwalk for the Cause.”
8
Impact SPRING 2010

Make your next gift online at dana-farber.org/give.
Research holds the key:
Anonymous donor fuels lung cancer study
Recognizing the vital role that intense scientific research can play in preventing
and curing devastating diseases like lung cancer, a donor wishing to remain
anonymous recently gave $2 million to fund the investigations of Pasi
Jänne, MD, PhD, and his team in the Carole M. and Philip L. Lowe Center for
Thoracic Oncology at Dana-Farber.
“As someone who has supported other hospital programs, I had a strong desire
to bring my philanthropy over to this particular area of research,” said the donor.
“I truly believe that scientific research is the key to curing health problems and to
learning how to best prevent and treat diseases like lung cancer.”
In the U.S. alone, this disease is diagnosed in 215,000 people annually, 15
percent of whom are never-smokers––people who have smoked less than 100
cigarettes in their lifetime. Recent discoveries have created a paradigm shift in
looking at lung cancer and recognizing that it is not just one disease. The focus has
now turned toward sub-classifying it based on genetic and biological composition
in order to make an accurate diagnosis and develop effective treatments.
An ongoing search
One example of this new way of understanding lung cancer is the 2004 discovery by
Jänne and his Dana-Farber colleagues, Lowe Center Director Bruce Johnson, MD,
and Matthew Meyerson, MD, PhD, co-director of the Center for Cancer Genome
Discovery, of the role that mutations of the epidermal growth factor receptor (EGFR)
gene play in lung cancer, specifically that of never-smokers. They found that in this
group of patients, EGFR has been altered in such a way that causes tumors to grow;
it is this EGFR finding that is now driving Jänne’s work to further classify the disease.
“We’re conducting a comprehensive analysis of never-smokers as a subgroup of
lung cancer patients,” said Jänne. “By recognizing that genetic alterations occur in
about half of our patients who don’t smoke, there is an expectation that there may
be other mutations out there as well.”
EGFR mutations are found in 35 percent of never-smokers, with 10 percent
harboring another genetic alteration (translocation) in the ALK gene. There are
current drugs for both genetic alterations and, so far, they have been very effective.
Jänne’s goal is to identify the mutations in the remaining 55 percent of patients,
and ultimately match specific genetic mutations to therapies that target each
altered gene. This anonymous gift supports Jänne’s and his colleagues’ work by
enabling them to launch clinical studies with a laboratory component to further
Dana-Farber’s Pasi Jänne, MD, PhD, is working to further classify subtypes of lung cancer by identifying
genetic mutations in order to develop more effective treatments.
define the genetic variations that occur in different subtypes of lung cancer. By
doing so, they can develop a new generation of drugs to target these variations,
creating novel, personalized treatment protocols for patients.
“Support of this type of research at the Institute is what made our initial
discovery of the EGFR mutation possible,” said Jänne. “I am incredibly grateful for
this tremendous commitment, which will enable us to build on what we know and
advance our understanding and treatment of lung cancer.” n
Men unite in the fight against
women’s cancers
After losing his wife, Amy, to ovarian cancer, Sheldon Simon became
passionately involved in conquering women’s cancers. Simon immediately
recognized there were scores of men willing to join him and help their
own wives, mothers, and daughters. He answered this call by creating the Dana-
Farber/Harvard Cancer Center (DF/HCC) Men’s Collaborative to Cure Women’s
Cancers, which supports breast and gynecologic cancer research.
Hoping to set the tone for support as the collaborative’s chairman, Simon
and his wife, Ruth Moorman, have pledged the program’s first major contribution:
a $100,000 gift. The gift also honors Moorman’s mother, who is currently battling
ovarian cancer.
“There is strength in numbers, and I
hope that through DF/HCC’s member
institutions, we can unite to honor the
women we love and make a difference
in others’ lives,” said Simon.
The couple’s gift to the collaborative
will support cutting-edge research and
novel cancer treatments, including
PARP inhibitors, which are a new
class of chemotherapy drugs that show
promise in certain breast and ovarian
cancers. In particular, women who
harbor disease-causing changes in the
BRCA1 or BRCA2 genes may receive
special benefit from PARP inhibitors.
Sheldon Simon and his wife, Ruth Moorman,
share a wish to conquer women’s cancers.
“I am excited about getting men involved in the support of women’s cancers, and
we will ensure funds raised support high-impact research anywhere in the cancer
center. Research has changed the face of cancer treatment, and I am confident the
collaborative will make a difference in the way women’s cancers are treated and,
someday, cured,” said DFCI Women’s Cancers Program Director J. Dirk Iglehart,
MD, the Anne E. Dyson Professor in Women’s Cancers at Harvard Medical School
and Charles A. Dana Senior Investigator in Human Cancer Genetics at Dana-Farber. n
A taste of success
Top restaurants across Western Massachusetts put their best fare forward Jan. 22 at
the 20th annual Chefs for Jimmy, presented by Winer Levsky Group of UBS Financial
Services, Inc., in honor of Neal Webber and the Kittredge Equipment Company. The
theme of this year’s event was “Let’s Play MONOPOLY ® ,” with 27 participating
eateries presenting dishes playing off the popular board game to the delight of the
event’s more than 1,000 attendees.
Though guests enjoyed an evening of fun and food, filling their plates and participating
in silent auctions and prize drawings, the Jimmy Fund proved to be the biggest
winner, as the event raised a final total of $109,000 to help conquer cancer, bringing
its cumulative giving to more than $1 million.
At the close of the event, Jimmy Fund Director Suzanne Fountain (center) and Event
Manager Kelly See (right) accepted a check representing the event’s success from
its organizers (left to right) Michael Katz, Barbara Sadowsky, an Institute trustee and
Jimmy Fund Council of Western Massachusetts president, and Andrew Cohen.
Impact SPRING 2010 9

Get involved, have fun, and beat cancer. Visit JimmyFund.org today.
Foundation extends critical
funding for survivorship
LIVESTRONG TM recently extended its support of Dana-Farber’s Lance
Armstrong Foundation (LAF) Adult Survivorship Program with a 15-month
grant totaling $266,000. This aid follows LIVESTRONG’s previous support,
which established DFCI’s Adult Survivorship Program and Clinic—a
LIVESTRONG TM Survivorship Center of Excellence. This continued funding
will allow for the expansion of the LAF
Adult Survivorship Clinic’s services,
while further integrating new survivorship
programs into the fabric of DFCI’s
mission to provide compassionate care
to its patients.
“Many patients describe a difficult transition from their initial treatment to
survivorship,” said the LAF’s Director of Navigation Services Caroline Huffman,
LCSW, MEd. “We chose Dana-Farber as a Center of Excellence because of its ability
to direct survivorship services and increase the effectiveness and integration of care.”
LIVESTRONG’s contribution will also enable the Institute to reach beyond its
own walls to advance its Community-Based Collaborative Survivorship Program
undertaken with several community health centers. It will also allow DFCI to
expand its mobile health efforts to reach survivors where they live and work
through the Survivorship on the Road program in conjunction with the Blum
Family Resource Center Van.
“There are 12 million cancer survivors today, and there will be nearly 20 million
by 2020,” said Kenneth Miller, MD, director of DFCI’s LAF Adult Survivorship
program. “Integrating survivorship throughout Dana-Farber and all points of
contact is increasingly important. LIVESTRONG’s gift is extremely helpful in
accomplishing that, and we are honored to be a LIVESTRONG TM Survivorship
Center of Excellence.” n
Hungry to help
Foodies and fundraisers wined and dined while rubbing elbows with some of Boston’s
culinary greats March 4 at the 12th annual Chefs Cooking for Hope event, hosted by
the all-volunteer Friends of Dana-Farber Cancer Institute. The evening featured small
plates of gastronomic fare skillfully prepared and presented by more than 50 of New
England’s leading chefs, restaurateurs, and caterers, along with a wide range of fine
wines and beverages, all generously donated to fuel the fight against cancer.
Above: Attendees enjoyed sampling everything from the raw to the refined, including
delectable dishes prepared by Honorary Chefs Jody Adams (left) of Cambridge’s
Rialto and Jeff Fournier of Newton’s 51 Lincoln. Guests were welcomed by Chefs
Cooking for Hope Co-chairs and Friends members (center, left to right) Nikki Lank
Bialow, Lisa London, and Lesley Prowda in the colossal atrium of downtown Boston’s
125 High Street.
GET YOUR PLATE TODAY. Go to jimmyfund.org/soxplate
Massachusetts
10
Silks strive to help others
by supporting lung cancer
clinical trials
Nearly 215,000 people are diagnosed with lung cancer each year in the U.S.,
and many would be surprised to learn that 10 – 15 percent are non-smokers.
To speed the development and testing of new treatments for patients,
Sherry and Bobby Silk recently gave $100,000 to establish the Silk Family Fund
for Thoracic Oncology Research at Dana-Farber. The fund is directed by Sherry’s
oncologist, Michael Rabin, MD, clinical director of the Carole M. and Philip L.
Lowe Center for Thoracic Oncology. The Silks’ gift also supports Mission Possible:
The Dana-Farber Campaign to Conquer Cancer.
Sherry and Bobby Silk’s $100,000 gift supports clinical trials in lung cancer led by Sherry’s oncologist,
Michael Rabin, MD.
“I never expected to end up at Dana-Farber,” said Sherry. “[Being diagnosed
with lung cancer] wasn’t my choice, but as long as it has been thrown at me, I have
to step up to the plate and help as many people as I can. Hopefully, this gift will
support a lot of people.”
The Silks have supported Dana-Farber for many years, and their most recent
and largest gift strengthens Rabin’s efforts to provide patients with the latest
therapeutic approaches. Rabin and his colleagues in the Lowe Center currently
lead an array of trials with therapies that target specific genetic mutations to
destroy cancer cells, overcome drug resistance, and combat metastasis.
“Sherry and Bobby’s generous support is critical in bringing new lung cancer
drugs into clinical trials for patients,” said Rabin. “This gift enables us to develop
new drug combinations and devise strategies to attack cancer-causing mutations
and reduce toxicity in patients.” n
Grateful patient supports
oncologist’s quest
to conquer mesothelioma
The past can impact a person’s
future in many ways. For
patients with the rare cancer
known as mesothelioma, the past is
tragically significant. Mesothelioma is
predominantly caused by exposure to
asbestos, but symptoms typically appear
30 – 50 years after initial exposure.
As a young man, Rowland Barrett
helped his father, a steamfitter, pack
asbestos around pipes. They were unaware
of the danger, and, decades later, Barrett
was diagnosed with mesothelioma.
He and his wife, Emilie, recently
David Jackman, MD, received support from
Rowland and Emilie Barrett to combat
mesothelioma, a type of cancer that affects
3,000 people each year in the U.S.
gave $100,000 to establish the Barrett Family Research Fund at DFCI. The fund
supports mesothelioma research led by Barrett’s oncologist, David Jackman, MD,
in the Carole M. and Philip L. Lowe Center for Thoracic Oncology.
“Dana-Farber has always been at the forefront of research, which is uppermost
in our minds as a family,” said Rowland Barrett. “Dr. Jackman is a delight to work
with, and both my wife and I are great fans of his.”
Barrett praised Jackman’s “all-hands-on-deck” approach, as the oncologist
proactively collaborates with investigators across Dana-Farber, Brigham and
Women’s Hospital, and other major institutions to broaden treatment options for
mesothelioma patients. Jackman is working on launching several clinical trials of
novel therapeutic agents.
“My team is leading a range of initiatives targeting this disease, with an emphasis on
bringing new therapies to patients,” said Jackman. “I am honored to receive the heartfelt
support of Rowland and Emilie Barrett, and their generosity will help us move our
research forward at an even faster pace.” n
10
Impact SPRING 2010

The Breast Cancer Research Foundation’s commitment
to finding cures stands strong
For nearly 17 years, the Breast Cancer Research Foundation (BCRF) has
generously supported clinical and translational research necessary to
advancing the prevention, treatment, and cure of breast cancer. This past year,
Dana-Farber received $1.4 million
in grants from the foundation to
ensure that investigators can
The
Breast
Cancer
Research
Foundation TM
continue to create a positive difference
for millions of women.
“BCRF’s scientific advisors know
that the stellar work of Dana-
Farber researchers is advancing our
understanding of how breast cancer
arises, and how to stop it in its
tracks,” said Peg Mastrianni, BCRF
Deputy Director. “The foundation is proud to support these investigators, who are
bringing us closer to our goal of prevention and a cure in our lifetime.”
The BCRF’s generosity is set to have a broad impact, as the grants will be
distributed to benefit the research of several Dana-Farber physician-scientists.
Continuous support, promising outcomes
The foundation’s commitment to eradicating breast cancer is reflected in its
continued support for DFCI’s researchers, such as Kornelia Polyak, MD, PhD,
of Medical Oncology, who will use this vital funding to compare tumors at
different stages of development to find the cell population responsible for
progression and resistance to therapy.
A grant is also helping William Kaelin, MD, of Medical Oncology, who is
analyzing the enzyme Eg1N2, whose absence in breast cancer cells impairs the
ability to reproduce and form tumors, thus paving the way for the creation of a
drug that targets Eg1N2.
Nancy Lin, MD, will utilize her grant to continue to front clinical trials
evaluating treatments for breast cancer that has metastasized to the brain.
For David Livingston, MD, chair of DFCI’s Executive Research Committee
and deputy director of Dana-Farber/Harvard Cancer Center, funding from the
BCRF means the capability to test the hypothesis that IRIS, one of the products
of BRCA1, brings forth cancerous behavior in healthy cells, making it a potential
drug target.
Aiming for targets
The BCRF is also applying its generosity to combat a specific subtype of the
disease: basal-like breast cancer.
Judy Garber, MD, MPH, director of the Friends of Dana-Farber Cancer Risk
and Prevention Program, will use her grant to continue investigations into the
effects of a promising new PARP inhibitor, which has shown exciting results in
women with BRCA1 and BRCA2 gene mutations, as well as to broaden her study
on basal-like breast cancer.
Ursula Matulonis, MD, director of Medical Gynecologic Oncology, and
Zhigang Wang, MD, PhD, in conjunction with Ross Berkowitz, MD, director of
the Gynecologic Oncology Center at Dana-Farber/Brigham and Women’s Cancer
Center and William H. Baker Professor of Medicine at Harvard Medical School,
will further investigate a number of unstable chromosomes shared in basal-like
breast cancer and high-grade serous ovarian cancer.
Lastly, J. Dirk Iglehart, MD, director of the Women’s Cancers Program, and
Andrea Richardson, MD, director of the Women’s Cancers Program Tissue Bank
at Dana-Farber, will capitalize on a special five-year research project that yielded
the discovery of a region of chromosome 8, which causes resistance to Adriamycin,
the most frequently used chemotherapy drug for breast cancer. This discovery will
lead them to the development of a clinical test for this chromosomal marker.
“Impactful cancer research is often difficult to find funding for and is timeconsuming.
It takes long-term commitment from dedicated foundations and
individuals,” said Iglehart. “This is the strength of the BCRF: it has staying power.” n
Wolpin wins award to propel
pancreatic cancer research
Dana-Farber’s Brian Wolpin, MD, MPH, has been honored with a
Physician-Scientist Early Career Award from the Howard Hughes Medical
Institute (HHMI) to advance his efforts to eradicate pancreatic cancer.
Through this award, Wolpin will receive $375,000 over the next five years.
“There is a great need for more physician-scientists to help translate basic
scientific discoveries into practical medical applications,” said William Galey,
director of HHMI’s Graduate Education and Medical Research Training
Programs. “This program helps promising doctors like Dr. Wolpin focus on this
type of research during a vulnerable stage in their careers.”
Wolpin will use the grant to advance his work identifying genetic and lifestyle
factors that predispose people to
pancreatic cancer. This entails
analyzing information about diet,
lifestyle choices, and inherited
genetic information from a large
group of individuals who developed
pancreatic cancer and comparing it
to similar data from healthy people
without the disease.
Wolpin has already used this
strategy to discover several genetic
alterations associated with the
future risk of developing pancreatic
cancer. Next, he hopes to reveal
additional factors that could help
identify individuals at high risk for
the disease.
“This award greatly accelerates
our efforts to identify genetic
and blood-based risk markers
for this disease,” said Wolpin. “It
may provide valuable insights
into disease prevention and novel
Brian Wolpin, MD, MPH, is conducting promising
pancreatic cancer research.
screening tests to identify the cancer
at its earliest stages.” n
Salkewicz makes DFCI
technology a top priority
Like so many people, William Salkewicz has had several family members
and friends affected by cancer. Wanting to do something to help ease
this burden, Salkewicz was inspired to learn about Dana-Farber and its
groundbreaking work during a recent meeting with his friend and mentor,
Institute Trustee Paul Severino. Severino told him about Dana-Farber’s High-
Tech Multidisciplinary Research Fund, which he and four others co-founded
to provide DFCI scientists with access to the tools that translate scientific
discoveries into new therapies more quickly than ever before.
Realizing the amazing potential of this project, Salkewicz made a gift to
support the High-Tech Fund in
honor of Severino for his steadfast
dedication to fueling cancer
research.
“Seeing Paul’s efforts to fight
cancer helped me realize that
there is a tremendous potential
for technology to bring more
effective treatments to patients,”
said Salkewicz. “I knew I wanted
to be a part of that.”
The High-Tech Fund is fueling
Dana-Farber’s overall goal of
personalized medicine: getting the
right drug to the right patient at
the right time. This goal is also a
main priority of Mission Possible:
The Dana-Farber Campaign to
Conquer Cancer.
“This gift significantly enhances
our investigators’ ability to
advance their work toward more
accurately and rapidly detecting,
guiding, and monitoring cancer
treatments,” said DFCI Chief
Scientific Officer Barrett Rollins,
MD, PhD. n
Institute Trustee Paul Severino’s (above) commitment
to cancer research inspired William Salkewicz to make
a gift supporting Dana-Farber’s technology platform.
Impact SPRING 2010 11

V Foundation grant advances
personalized cancer care
Jim Valvano, former North Carolina State University basketball coach and
award-winning broadcaster, believed passionately that money was needed
for cancer research.
“It may save my children’s lives. It may save someone you love,” he said. The
words ring as true in 2010 as they did in 1993 when he and ESPN launched The
V Foundation for Cancer Research.
Diagnosed in June 1992 with
an advanced cancer of unknown
origin, Valvano died within a year,
but he left behind an extraordinary
legacy: a foundation that has
raised $95 million, awarded more than 350 grants to researchers nationwide, and
brought us closer to a world without cancer.
Continuing its longstanding relationship with Dana-Farber, The V Foundation
recently awarded Rameen Beroukhim, MD, PhD, $200,000 to further his research
in cancer genomics.
“Dr. Beroukhim is a prime example of our V Scholar Program at its best,” said
Nick Valvano, CEO of The V Foundation. “By investing in promising researchers
like Dr. Beroukhim, we hope to accelerate the impact of their contributions to
cancer discovery and care.”
The V Foundation grant enables Beroukhim to continue his investigation
of genetic alterations—specifically, extra copies of certain genes—across all
types of cancer to identify the mutations that are contributing most to cancer
development. The next phase of Beroukhim’s research will take advantage of
rapidly evolving technology, which allows researchers to sequence DNA even
in small tissue samples, to determine which of the mutations are present in a
patient’s tumor.
Beroukhim explained, “With this knowledge in hand, we can personalize
medicine, selecting therapies based upon the genetic profile of each patient’s
tumor. I am tremendously grateful to The V Foundation for its support.” n
Leading the way
Saunders helps DFCI researchers
explore underlying causes of
non-smoking lung cancer
Nearly two decades ago,
Roger Saunders was
forced to confront a
medical mystery when his first
wife, Nina—a 57-year-old nonsmoker—was
diagnosed with
lung cancer.
Nina’s Dana-Farber physician,
Robert J. Mayer, MD, explained
that 10 – 15 percent of lung
cancers arise in non-smokers—a
statistic that still holds true today.
Equally puzzling is that nonsmoking
women are two to three
times more likely to develop lung
cancer than non-smoking men.
After Nina died in 1991,
Saunders remained connected
to the Institute and became a
Roger and Norma Saunders have established the
Saunders Family Research Fund to bolster studies into
thoracic oncology at DFCI.
member of Dana-Farber’s Hematologic Oncology Visiting Committee in 1999.
Inspired by the great strides Dana-Farber scientists have made in understanding
and treating blood cancers, Saunders began to wonder whether similar advances
could help solve the mystery of Nina’s illness.
Now, Saunders and his current wife, Norma, have made a major contribution
to Mission Possible: The Dana-Farber Campaign to Conquer Cancer. Their gift
supports non-smoking lung cancer research by Dana-Farber’s Matthew Meyerson,
MD, PhD, co-director of the Center for Cancer Genome Discovery. The studies
are directed by Mayer—now the faculty vice president for Academic Affairs at
Dana-Farber and the Stephen B. Kay Family Professor of Medicine at Harvard
Medical School.
“Dana-Farber is an international resource, and I want to support the
important work going on there,” said Saunders. “In particular, I hope this gift
will shed some light on why lung cancer affects people who have never smoked.”
Meyerson’s discovery of genetic mutations fueling some non-smoking lung
cancers is already shaping the way these patients are treated.
“This gift will help us learn even more about the genetic roots of this poorly
understood disease,” he said. n
GET ON THE RIGHT COURSE TO FIGHT CANCER SM
Founded in 1999, the Dana-Farber Leadership Council (DFLC) is an all-volunteer
organization dedicated to advancing the Institute’s lifesaving work in research and
patient care through advocacy, financial support, and leadership. On Feb. 4, DFLC
Co-chairs Jeff Goldstein (right) and Russell Norris announced that this mission had
been bolstered in 2009 by the more than $460,000 raised in support of the Dana-
Farber Leadership Council Presidential Initiatives Fund.
At the reception celebrating this achievement, DFLC members were recognized for
their hard work in raising funds for Dana-Farber through the DFLC Annual Fund and
their participation in several events, including the Boston Marathon ® Jimmy Fund
Walk, Rally Against Cancer SM , and the Dana-Farber Leadership Council Golf Tournament.
Patient speaker Paul Salines and Bambi Mathay, a massage therapist in the
Leonard P. Zakim Center for Integrative Therapies at Dana-Farber, spoke to the
tangible progress made possible by this success, spurring the DFLC’s motivation
to continue its fundraising efforts in 2010 and beyond.
RATHER
BE GOLFING?
FIND OUT HOW YOUR FAVORITE PASTIME
CAN HELP CANCER PATIENTS EVERYWHERE
JimmyFundGolf.org
866-521-GOLF
12
Impact SPRING 2010

Play ball at Fenway! Visit JimmyFundFantasyDay.org.
Stand Up To Cancer continued from page 1
Over the next three years, four Dana-Farber
investigators, including Loren Walensky, MD, PhD,
will each receive a $750,000 SU2C Innovative
Research Grant that supports the next generation
of leaders in cancer research.
could reveal new targets for cancer
treatment.
“When you look back on any
scientific breakthrough, whether
it was designing the first vaccine
or going to the moon, there had
to be a new way of thinking and
doing,” Walensky said. “The Stand
Up To Cancer grants propel new
ideas that may lead to revolutionary
approaches for treatment.”
With support from SU2C,
Roberts will test the ability of
experimental therapies to reverse
the impact of cancer-causing
mutations in two extremely
aggressive pediatric cancers:
malignant rhabdoid and atypical
teratoid/rhabdoid tumors.
Stegmaier is harnessing the
SU2C grant to apply a multidisciplinary
approach developed at DFCI to understanding and targeting a
cancer-promoting protein in Ewing sarcoma, the second most common bone
cancer in children.
Meanwhile, Weinstock will utilize a novel genetic profiling system to discover
new mutations that drive cancer growth and progression. His unique system
makes tumor profiling faster, more efficient, and more precise, and has already led
to the discovery of a key mutation in certain cases of acute lymphocytic leukemia.
According to SU2C, each of these research initiatives holds promise to push the
boundaries of understanding and treating cancer—a mission that the organization
shares with Dana-Farber. n
EXPERIENCE
FENWAY PARK
LIKE NEVER BEFORE
Taking a stand: Foundation
battles pediatric cancers
In 2000, Alexandra Scott, a
4-year-old cancer patient,
decided to sell lemonade on
her front lawn in an effort to
raise money to find a cure for the
disease that affected her and so
many other children. Though,
sadly, Alex lost her battle at
age 8, her family has kept her
commitment alive through
the Alex’s Lemonade Stand
Foundation (ALSF). This year,
the ALSF distributed grants
totaling nearly $4 million to 18
institutions and universities in
13 states across the U.S.
Alex’s Lemonade Stand Foundation is committed to
supporting organizations in memory of its namesake,
Alexandra Scott, who lost her battle with cancer.
Lewis Silverman, MD, director of Inpatient Oncology at Dana-Farber, was
one recipient, receiving a $250,000, two-year Program Infrastructure Award
designed to speed the process of enrolling children with cancer in clinical trials.
Additionally, DFCI’s Rani George, MD, PhD; Ujwal Pyati, PhD; and Katherine
Janeway, MD, each received a two-year Young Investigator Award of $80,000,
which provides junior researchers and physicians with the necessary funding to
pursue promising research ideas.
“Alex herself was vigilant that if we worked together, we could move toward
a cure,” said Jay Scott, Alex’s father. “She was certainly right, and the funding of
these projects is leading the way to one day eradicating childhood cancer.”
Silverman’s Program Infrastructure Award supports the creation of a
childhood leukemia translational research program that will develop and
implement more effective and less toxic therapies for children while efficiently
facilitating the translation of laboratory findings into clinical trials.
“New and more effectual therapies are urgently needed for children with
leukemia, both to increase cure rates and to decrease treatment-related side effects,”
said Silverman. “The support awarded by Alex’s Lemonade Stand Foundation
will allow us to develop the research infrastructure necessary to successfully move
findings from our world-renowned laboratories into clinical practice.” n
AUGUST 29
Batting, Fielding
& Fan Packages Available
Purchase your tickets today at
JimmyFundFantasyDay.org
Leaders of the pack
TUNE IN...
STRIKE OUT CANCER!
AUGUST 19 & 20
6 A.M. TO MIDNIGHT – BOTH DAYS!
jimmyfundradiotelethon.org
There is a big reason why the Boston Marathon ® Jimmy Fund Walk presented by
Hyundai raised $6 million in 2009 and has raised more than $66 million cumulatively:
thousands of dedicated walkers. Those Pacesetters—walkers who raised $1,000 or
more—and top team captains of teams that raised more than $10,000 were honored
for their tremendous fundraising efforts at the Extra Mile Brunch March 21, held at
the Boston Marriott Copley Place. Above: On display at the brunch were posters
featuring the names of the top teams and all 1,433 Pacesetters.
To illustrate the importance of fundraising, keynote speaker David Weinstock, MD,
of Hematologic Oncology at Dana-Farber, spoke about the revolutionary research
and patient care practices that have been made possible thanks to the funds raised
by walkers.
The 2010 Walk season is well underway, with hundreds of walkers already registered
to tackle routes along the historic Boston Marathon ® course and to conquer cancer.
To learn more or register to walk Sunday, Sept.12, visit JimmyFundWalk.org.
Impact SPRING 2010 13

DFMC continued from page 1
Weaver. “Without these dedicated runners helping to support this research, we
cannot begin to unravel the mysteries of cancer; Wayne and I are proud to support
them.”
This year, the team is set to raise an anticipated $4.4 million for the program—an
achievement made possible only by the commitment its runners have to Dana-Farber
and the generosity of their friends, family members, and other donors. The team
itself is part of the reason that DFMC runners continue to give back year after year.
Patient Partner Anthony Stacanto, an acute lymphoblastic leukemia patient at Dana-Farber, is Aimee
McGuire’s main motivation to run for the DFMC each year.
A part of the “family”
As a Boston Marathon qualifier, Aimee McGuire does not need to fundraise in
order to race in the country’s premiere running event. Yet the five-time DFMC
runner does so because of the experience of being part of this “family” of runners.
“When I ran my first Boston-qualifying time in 2008, it didn’t even occur to
me to stop being a part of the DFMC team,” explained McGuire, a DFMC Board
member. “After experiencing what the program is all about, running the marathon
becomes greater than the 26.2 miles from Hopkinton to Boylston Street.”
McGuire has cumulatively raised more than $125,000 for the Barr Program,
not missing a fundraising season—even when an injury prevented her from
running the race in 2007.
Motivation from around the globe
The DFMC team extends around
the globe, with members training
both near and far, and, in the the
case of Jack Cumming, very far.
Working for an international organization
that focuses on women’s
health and the early diagnosis of
breast and cervical cancers, Cumming’s
inspiration comes from the
women he meets each day while
traveling around the world.
“Through my occupation, I
unfortunately see cancer all the time
when meeting with radiologists,
surgeons, oncologists, and patients–
many of whom I’ve watched pass
away,” Cumming reflected. “Dana-
Farber is a wonderful institution
working to cure this disease, and
being a part of the DFMC team
makes it easy to support.”
Much like his teammates in
Boston and elsewhere, Cumming’s
motivation to run comes from
wherever he may be and whomever
he might meet that day. Whether he
is running in a forest in Germany
or getting in an early run in Hong
Actress Valerie Bertinelli runs the marathon with her
trainer and DFMC teammate, Christopher Ross Lane.
Kong before the city wakes up, Cumming keeps on with his training because he
knows that his running can help Dana-Farber have a global impact for cancer
patients around the world. n
MAKE YOUR
RUNNING
MEAN MORE
Conquering women’s cancers:
new decade, new hope
Join Running the Race Against Cancer®
and compete in famed races while
raising funds for Dana-Farber Cancer
Institute and the Jimmy Fund’s
lifesaving mission.
Learn more at
RunDanaFarber.org
The seventh annual Women’s Cancers Program (WCP) Executive Council Breakfast,
held April 6 at the Four Seasons Hotel Boston, drew more than 250 women dedicated
to making a difference in the lives of those diagnosed with breast and gynecologic
cancers. Headed by Co-chairs Tracey E. Flaherty, Institute Trustees Jane Jamieson and
Beth Terrana, and Honorary Chair and Institute Trustee Susan F. Smith, the Executive
Council seeks to raise funds for Dana-Farber’s WCP and accelerate innovative, earlystage
research, create advocates, and educate women about the latest advances and
challenges in treating women’s cancers.
Above, left to right: After describing to the crowd how unprecedented advances in
technology now make it possible for newly diagnosed ovarian cancer patients and
those whose cancer has recurred to be screened for the most common cancer-related
genetic mutations—the first step toward personalized care—Dana-Farber’s William
Hahn, MD, PhD, co-director of the Center for Cancer Genome Discovery, and Ursula
Matulonis, MD, medical director of Gynecologic Oncology, joined Co-chairs Flaherty,
Terrana, and Jamieson in celebrating the council’s continued success.
Guest speaker Joyce Kulhawik, longtime arts and entertainment critic for Boston’s CBS
affiliate and an ovarian cancer survivor, stressed how difficult the disease can be to
diagnose and expressed her excitement about Dana-Farber’s research progress. She
applauded the WCP Executive Council, which has raised more than $7 million to date,
funding 15 promising research studies.
14
Impact SPRING 2010

Have you included Dana-Farber in your estate plans? Contact us at 617-632-3756.
Sanders family shares
Institute’s vision of
personalized medicine
Institute Trustee Rebecca Sanders and her husband, Bill, are active supporters
of Dana-Farber, organizing fundraising events and serving on the Visiting
Committee for Hematologic Oncology. As close partners of the Institute, the
couple have recognized that technology, one of DFCI’s top priorities, is key to
advancing cancer research and care
in the next decade.
Recently, they gave $100,000
to establish the Sanders Family
Genomics Technology Fund,
managed under the direction of
Levi Garraway, MD, PhD, principal
investigator in Dana-Farber’s Center
for Cancer Genome Discovery. Their
gift will support the OncoMap,
a novel technology developed
at Dana-Farber that can detect
hundreds of known cancer-related
mutations in more than 1,000
tumor samples at the same time.
Their gift also supports Mission
Possible: The Dana-Farber Campaign
to Conquer Cancer.
Institute Trustee Rebecca Sanders and her husband,
Bill, are excited about the progress Dana-Farber is
making toward personalized medicine for every patient.
“Bill and I are pleased to support
a project with applications to many
different forms of cancer,” said
Rebecca Sanders. “This project gives
us hope that rapid advancements in treatment will be made and that conquering
cancer is possible in the near future.”
The OncoMap represents a critical step toward the delivery of personalized
medicine because it will uncover which mutations actually drive tumor growth in
each individual patient. Most importantly, this can be done quickly, accurately,
and on a larger scale than ever before.
“Dana-Farber is deeply committed to the goal of profiling every patient’s
tumor for the presence of ‘actionable’ cancer gene mutations, but this remains a
challenging and costly endeavor,” said Garraway. “I feel enormous gratitude and
respect for Rebecca and Bill Sanders for partnering with us in pursuit of this goal.” n
George Stone built a legacy
at Dana-Farber
Through his development and construction business, George Stone made a
distinct mark on the Baltimore, Md., landscape. When he became ill with
esophageal cancer in 2004, Stone turned to Dana-Farber’s Jeffrey Meyerhardt,
MD, MPH, for his treatment and care. From that point on, Stone made
a similarly distinct impression on
Dana-Farber.
“George was extremely
impressed with everyone at the
Institute,” said Stone’s close friend
Carole Gilbert, who often traveled
with him to Dana-Farber. “He
knew Dr. Meyerhardt was doing
great research, and he wanted to be
a part of it.”
Sadly, Stone lost his battle
with cancer in 2006. Before his
passing, however, he made it clear
that he wanted to build a legacy
at Dana-Farber that would impact
the future of cancer research. A
gift of real estate from the George
W. Stone Trust resulted in more
than $221,500 to support the
Gastrointestinal Cancer Treatment
Center and Meyerhardt’s research.
This bequest will provide muchneeded
support for clinical trial
During his battle with esophageal cancer, George
Stone made a bequest to Dana-Farber to thank
his caregivers.
infrastructure as investigators test new drug agents for gastrointestinal cancers,
including esophageal cancer. It will also support research that will help improve
the process for selecting treatments for patients with these types of cancers.
“George Stone was truly a special person,” said Meyerhardt. “He traveled here
from Maryland for his care and always arrived with a positive attitude and spirit.
He constantly made me and the staff laugh. His personality was infectious and
lives on through this gift.” n
Golfers honored for going
the distance
Join our fight against cancer.
Establish a Charitable Gift Annuity (CGA) at Dana-Farber Cancer
Institute. In return, Dana-Farber will pay you a fixed income for life,
a portion of which is tax-free. Your gift of cash or securities creates
an opportunity like no other: to aid in our lifesaving mission while
receiving a guaranteed rate of return for the rest of your life.
To learn more, please contact Alice Tobin Zaff at
800-535-5577 or e-mail Alice_Zaff@dfci.harvard.edu
Golf tournament coordinators and volunteers who took their fights against cancer to
the links were honored at the annual Jimmy Fund Golf Appreciation Night, held Feb. 5
at The International in Bolton, Mass. The event recognized the hard work and dedication
displayed during the 2009 season, which tallied $6.1 million for Dana-Farber.
Several tournaments received awards recognizing top fundraising, fundraising growth,
anniversaries, and new tournaments. In addition, the prestigious Ken Coleman Extra
Mile Award, given to volunteers who emulate the late sportscaster’s hard work and
devotion to the Jimmy Fund, was presented to several deserving volunteers.
Above: The Foley family, (left to right) Brian, Connor, Claire, Annmarie, and Jim Foley
were honored for their Jimmy Fund Open golf tournament, which has collectively
raised more than $250,000 since 1990. Alan Krensky (far right), director of the Colpitts
World Travel Chips In for Cancer tournament, was honored for helping to raise
more than $650,000 over the past two decades.
Impact SPRING 2010 15

Impact
Spring 2010
Non-profit Org.
U.S. Postage
PAID
Dana-Farber
Dana-Farber Cancer Institute
Division of Development & The Jimmy Fund
10 Brookline Place West, 6th Floor
Brookline, MA 02445-7226
ELECTRONIC SERVICE REQUESTED
dana-farber.org and jimmyfund.org
THANKING THOSE WHO MAKE A DIFFERENCE.
In January, news anchor Katie Couric of “CBS
Evening News with Katie Couric” visited Dana-Farber
and interviewed Ronald DePinho, MD, director of
DFCI’s Belfer Institute for Applied Cancer Science,
for an in-depth report on cancer care today and the
progress toward personalized medicine.
June
16-17
Swim Across America
7-8
Pan-Massachusetts Challenge (PMC)
8-10
June 11-
July 25
Jimmy Fund Scooper Bowl®
Presented by FedEx
Dig in to the summer’s
coolest way to fight cancer
at this 28th annual all-youcan-eat
ice cream festival,
featuring entertainment,
music, and more Tuesday
through Thursday from
12 – 8 p.m. at Boston City
Hall Plaza. For more information,
contact Dana Kelly
at 617-632-3863 or visit scooperbowl.org.
Jimmy Fund/Variety Children’s
Charity Theatre Collections
Show your support for the Jimmy Fund by volunteering
at participating National Amusements theatres and
collecting contributions during the summer blockbuster movie
season. For more information, contact Kimberly Chisholm at
617-632-5091 or kimberly_chisholm@dfci.harvard.edu.
Dive in and support the
David B. Perini, Jr. Quality
of Life Clinic at DFCI by
participating in the Boston
Harbor Islands Swim July
16, a 22-mile, relay-style
event, or join swimmers
ages 12 and older in a halfmile
recreational or onemile
competitive swim the
following day at Nantasket
Beach in Hull, Mass.
For more information,
contact Dana Kelly at
617-632-3863 or visit
jimmyfund.org/swim.
17-18 Mass Dash
Run across Massachusetts in this inaugural 200-mile, non-stop
relay benefiting the Jimmy Fund. Follow along the beautiful,
scenic course from Lanesboro, Mass., to Boston and help
conquer cancer. For more information, contact Meghan
McGovern at 617-632-1970 or visit massdashrelay.org.
Get ready to ride in the 31st annual bike-a-thon benefiting
cancer research and treatment at Dana-Farber. Team up with
cyclists from around the globe as they travel across the Commonwealth,
covering distances that range from 47 – 190
miles. To learn more about participating or to support a rider,
call 800-WE-CYCLE or visit pmc.org.
19-20
WEEI/NESN Jimmy Fund
Radio-Telethon
Tune in as the Boston Red
Sox battle in a two-game
homestand—and unite with
Red Sox Nation to conquer
cancer. Hear from doctors,
patients, and celebrities as
they share their moving
stories during this 36-hour
live broadcast on WEEI Sports Radio Network and New
England Sports Network (NESN). For details and volunteer
information, contact Katherine Hargadon at 877-738-1234
or visit jimmyfundradiotelethon.org.
September
July
August
12
Boston Marathon® Jimmy Fund Walk
Presented by Hyundai
July-
August
Jimmy Fund Little League Program
Take a swing at cancer along with New England Little
League baseball and softball players as they compete in
local tournaments. To support a specific team or player, or
to get involved, contact Amy Powers at 617-632-3613 or
amy_powers@dfci.harvard.edu.
6
Joe Cronin Memorial Fishing
Tournament
Reel in much-needed funds for Dana-Farber and the
Jimmy Fund at this 17th annual bluefish tournament
held at Nauticus Marina in Osterville, Mass. For more
information, contact Kimberly Chisholm at 617-632-5091
or visit joecroninfishing.com.
Take steps to conquer all forms of
cancer during this all-day, familyfriendly
event benefiting the Jimmy
Fund. With four routes ranging from
3 – 26.2 miles, there is a distance
for all ages and levels of ability.
Register today at JimmyFundWalk.org
or call 866-JF-1-WALK.
For more information on all Jimmy Fund and Dana-Farber events, go to jimmyfund.org or dana-farber.org.